Literature DB >> 20400508

Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.

Kannan Gunasekaran1, Martin Pentony, Min Shen, Logan Garrett, Carla Forte, Anne Woodward, Soo Bin Ng, Teresa Born, Marc Retter, Kathy Manchulenko, Heather Sweet, Ian N Foltz, Michael Wittekind, Wei Yan.   

Abstract

Naturally occurring IgG antibodies are bivalent and monospecific. Bispecific antibodies having binding specificities for two different antigens can be produced using recombinant technologies and are projected to have broad clinical applications. However, co-expression of multiple light and heavy chains often leads to contaminants and pose purification challenges. In this work, we have modified the CH3 domain interface of the antibody Fc region with selected mutations so that the engineered Fc proteins preferentially form heterodimers. These novel mutations create altered charge polarity across the Fc dimer interface such that coexpression of electrostatically matched Fc chains support favorable attractive interactions thereby promoting desired Fc heterodimer formation, whereas unfavorable repulsive charge interactions suppress unwanted Fc homodimer formation. This new Fc heterodimer format was used to produce bispecific single chain antibody fusions and monovalent IgGs with minimal homodimer contaminants. The strategy proposed here demonstrates the feasibility of robust production of novel Fc-based heterodimeric molecules and hence broadens the scope of bispecific molecules for therapeutic applications.

Mesh:

Substances:

Year:  2010        PMID: 20400508      PMCID: PMC2885242          DOI: 10.1074/jbc.M110.117382

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  Bispecific human IgG by design.

Authors:  P Carter
Journal:  J Immunol Methods       Date:  2001-02-01       Impact factor: 2.303

2.  Helix-stabilized Fv (hsFv) antibody fragments: substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain.

Authors:  K M Arndt; K M Müller; A Plückthun
Journal:  J Mol Biol       Date:  2001-09-07       Impact factor: 5.469

3.  Redesigning an antibody fragment for faster association with its antigen.

Authors:  Jonathan S Marvin; Henry B Lowman
Journal:  Biochemistry       Date:  2003-06-17       Impact factor: 3.162

4.  FATCAT: a web server for flexible structure comparison and structure similarity searching.

Authors:  Yuzhen Ye; Adam Godzik
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

5.  Energy functions for protein design: adjustment with protein-protein complex affinities, models for the unfolded state, and negative design of solubility and specificity.

Authors:  Navin Pokala; Tracy M Handel
Journal:  J Mol Biol       Date:  2005-01-20       Impact factor: 5.469

6.  'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization.

Authors:  J B Ridgway; L G Presta; P Carter
Journal:  Protein Eng       Date:  1996-07

7.  An efficient route to human bispecific IgG.

Authors:  A M Merchant; Z Zhu; J Q Yuan; A Goddard; C W Adams; L G Presta; P Carter
Journal:  Nat Biotechnol       Date:  1998-07       Impact factor: 54.908

8.  Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library.

Authors:  S Atwell; J B Ridgway; J A Wells; P Carter
Journal:  J Mol Biol       Date:  1997-07-04       Impact factor: 5.469

Review 9.  Molecular engineering and design of therapeutic antibodies.

Authors:  Leonard G Presta
Journal:  Curr Opin Immunol       Date:  2008-08       Impact factor: 7.486

10.  Identification of potent human anti-IL-1RI antagonist antibodies.

Authors:  Zoey L Fredericks; Carla Forte; Irene V Capuano; Hongxing Zhou; Tim Vanden Bos; Paul Carter
Journal:  Protein Eng Des Sel       Date:  2004-01       Impact factor: 1.650

View more
  106 in total

1.  Sequencing a Bispecific Antibody by Controlling Chain Concentration Effects When Using an Immobilized Nonspecific Protease.

Authors:  Robert A D'Ippolito; Maria C Panepinto; Keira E Mahoney; Dina L Bai; Jeffrey Shabanowitz; Donald F Hunt
Journal:  Anal Chem       Date:  2020-07-13       Impact factor: 6.986

2.  A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.

Authors:  Gregory L Moore; Cristina Bautista; Erik Pong; Duc-Hanh T Nguyen; Jonathan Jacinto; Araz Eivazi; Umesh S Muchhal; Sher Karki; Seung Y Chu; Greg A Lazar
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

3.  World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.

Authors:  Eugen Dhimolea; Janice M Reichert
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

Review 4.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

5.  Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.

Authors:  Christoph Spiess; Jack Bevers; Janet Jackman; Nancy Chiang; Gerald Nakamura; Michael Dillon; Hongbin Liu; Patricia Molina; J Michael Elliott; Whitney Shatz; Justin M Scheer; Glen Giese; Josefine Persson; Yin Zhang; Mark S Dennis; James Giulianotti; Prateek Gupta; Dorothea Reilly; Enzo Palma; Jianyong Wang; Eric Stefanich; Heleen Scheerens; Germaine Fuh; Lawren C Wu
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

6.  Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry.

Authors:  Wolfgang Schaefer; Hans R Völger; Stefan Lorenz; Sabine Imhof-Jung; Jörg T Regula; Christian Klein; Michael Mølhøj
Journal:  MAbs       Date:  2015-10-23       Impact factor: 5.857

Review 7.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

8.  Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies.

Authors:  Christoph Spiess; Mark Merchant; Arthur Huang; Zhong Zheng; Nai-Ying Yang; Jing Peng; Diego Ellerman; Whitney Shatz; Dorothea Reilly; Daniel G Yansura; Justin M Scheer
Journal:  Nat Biotechnol       Date:  2013-07-07       Impact factor: 54.908

9.  Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.

Authors:  K J Froning; A Leaver-Fay; X Wu; S Phan; L Gao; F Huang; A Pustilnik; M Bacica; K Houlihan; Q Chai; J R Fitchett; J Hendle; B Kuhlman; S J Demarest
Journal:  Protein Sci       Date:  2017-07-31       Impact factor: 6.725

Review 10.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.